Halia Therapeutics Secures FDA Fast Track for Ofirnoflast
LEHI, Utah, June 15, 2026 Halia Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LEHI, Utah, June 15, 2026 Halia Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted...
SAN DIEGO, June 15, 2026 Halozyme Therapeutics, Inc. has confirmed that it expects zero to minimal impact on royalty...
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
WILMINGTON, Del. & SAN FRANCISCO, May 19, 2026 Incyte and Edison Scientific have announced a strategic collaboration aimed at...
SAN ANTONIO, Texas, May 19, 2026 Valion Bio, Inc. has announced a high-level joint engagement with senior officials from...
CARY, N.C. and BRADENTON, Fla., May 20, 2026 Continuity Biosciences has announced the initiation of a Phase I first-in-human...
SAN DIEGO and MENLO PARK, Calif., May 6, 2026 Halozyme Therapeutics and Oruka Therapeutics announced a global exclusive collaboration...
DORTMUND, Germany, March 17, 2026 iDEL Therapeutics announced the successful close of a €9 million seed financing round led...
February 25, 2026 – Bagsværd, Denmark & Boston, Massachusetts, USA Novo Nordisk and Vivtex Corporation have announced a strategic...
